| First Author | Yu X | Year | 2020 |
| Journal | Cancer Cell | Volume | 37 |
| Issue | 6 | Pages | 850-866.e7 |
| PubMed ID | 32442402 | Mgi Jnum | J:290360 |
| Mgi Id | MGI:6437968 | Doi | 10.1016/j.ccell.2020.04.013 |
| Citation | Yu X, et al. (2020) Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity. Cancer Cell 37(6):850-866.e7 |
| abstractText | Anti-CD40 monoclonal antibodies (mAbs) comprise agonists and antagonists, which display promising therapeutic activities in cancer and autoimmunity, respectively. We previously showed that epitope and isotype interact to deliver optimal agonistic anti-CD40 mAbs. The impact of Fc engineering on antagonists, however, remains largely unexplored. Here, we show that clinically relevant antagonists used for treating autoimmune conditions can be converted into potent FcgammaR-independent agonists with remarkable antitumor activity by isotype switching to hIgG2. One antagonist is converted to a super-agonist with greater potency than previously reported highly agonistic anti-CD40 mAbs. Such conversion is dependent on the unique disulfide bonding properties of the hIgG2 hinge. This investigation highlights the transformative capacity of the hIgG2 isotype for converting antagonists to agonists to treat cancer. |
